Table 2.
Best Overall Responsea
| Total Patients (n = 95) | |
|---|---|
| CBR at week 24, n (%) [95% CI] b | 39 (41.1) [31.1–51.6] |
| ORR, n (%) [95% CI] c | 8 (8.4) [3.7–15.9] |
| Best overall response, n (%) | |
| CR | 1 (1.1) |
| PR | 7 (7.4) |
| SD | 47 (49.5) |
| PD | 32 (33.7) |
| Non-CR/non-PD, n (%) | 3 (3.2) |
| DCR, n (%) [95% CI] d | 58 (61.1) [50.5–70.9] |
CBR, clinical benefit rate; CR, complete response; DCR, disease control rate; NCRNPD, non-CR, non-PD; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.
a
Local investigator assessment per Response Evaluation Criteria in Solid Tumors version 1.1. Patients with measurable disease at baseline: n = 75; patients with only nonmeasurable disease at baseline: n = 20. Five patients discontinued without postbaseline tumor evaluation.
b
CBR: patients with CR, PR, SD, or NCRNPD at week 24.
c
ORR: patients with CR or PR.
d
DCR: patients with CR, PR, SD, or NCRNPD at any time during the study.